LeMaitre Vascular (NASDAQ:LMAT) issued its earnings results on Thursday. The medical instruments supplier reported $0.28 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.28, MarketWatch Earnings reports. LeMaitre Vascular had a return on equity of 12.32% and a net margin of 15.41%. LeMaitre Vascular updated its Q2 2021 guidance to 0.280-0.360 EPS and its Q2 guidance to $0.28-0.36 EPS.
LMAT stock traded down $1.39 during midday trading on Friday, reaching $52.47. The stock had a trading volume of 422,146 shares, compared to its average volume of 124,004. LeMaitre Vascular has a 52-week low of $23.40 and a 52-week high of $54.96. The company has a current ratio of 2.30, a quick ratio of 1.27 and a debt-to-equity ratio of 0.23. The company’s fifty day simple moving average is $49.52 and its 200 day simple moving average is $43.13. The company has a market cap of $1.08 billion, a price-to-earnings ratio of 56.42, a price-to-earnings-growth ratio of 3.52 and a beta of 1.43.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 25th. Stockholders of record on Tuesday, March 9th were paid a dividend of $0.11 per share. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.10. The ex-dividend date of this dividend was Monday, March 8th. This represents a $0.44 dividend on an annualized basis and a dividend yield of 0.84%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 50.00%.
Several equities research analysts have recently weighed in on LMAT shares. Zacks Investment Research lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Thursday. Roth Capital reaffirmed a “neutral” rating on shares of LeMaitre Vascular in a report on Tuesday, March 2nd. KeyCorp started coverage on shares of LeMaitre Vascular in a report on Friday, February 12th. They issued a “sector weight” rating on the stock. Barrington Research increased their target price on shares of LeMaitre Vascular from $49.00 to $59.00 and gave the stock an “outperform” rating in a research report on Friday. Finally, Lake Street Capital increased their price objective on shares of LeMaitre Vascular from $55.00 to $65.00 and gave the company a “buy” rating in a research note on Friday. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $46.33.
In related news, insider Trent G. Kamke sold 10,004 shares of the stock in a transaction dated Monday, March 1st. The stock was sold at an average price of $51.28, for a total transaction of $513,005.12. Following the transaction, the insider now directly owns 3,735 shares in the company, valued at $191,530.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO George W. Lemaitre sold 2,100 shares of the stock in a transaction dated Wednesday, March 10th. The shares were sold at an average price of $49.76, for a total value of $104,496.00. Following the completion of the sale, the chief executive officer now owns 2,692,833 shares of the company’s stock, valued at approximately $133,995,370.08. The disclosure for this sale can be found here. Insiders have sold a total of 132,816 shares of company stock valued at $6,728,329 over the last three months. Corporate insiders own 16.50% of the company’s stock.
About LeMaitre Vascular
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.
Further Reading: After-Hours Trading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: Dual Listing What You Need to Know
There are people who will say the day of set it and forget it retirement accounts are over. But it’s a narrative we’ve heard before. The truth is the formula for saving for and enjoying a comfortable retirement, like the formula for weight loss, hasn’t really changed. A lot depends on whether an individual has the discipline to see it through.
Dividend stocks remain one of the core elements of a retirement portfolio. As individuals near retirement the ability to reinvest dividends allows for a greater total return. And once individuals need to live off their portfolio, the dividends provide a source of income without having to tap their principal.
However, not all dividend stocks are the same and many investors get sucked in by the allure of a high-yield dividend stock. But what you’re really looking for are companies with a history of increasing its dividend. The ability to increase a dividend over time illustrates that the company has a business model that can hold up regardless of how the broader economy is performing.
In this special presentation, we’ll highlight seven stocks that individuals can buy today to capture a stable, recurring dividend.